Welcome to our dedicated page for GENMAB A/S SEC filings (Ticker: GMAB), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on GENMAB A/S's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time SEC filing updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into GENMAB A/S's regulatory disclosures and financial reporting.
Genmab A/S submitted a Form 6-K as a foreign private issuer, furnishing a company announcement dated November 20, 2025 about the grant of restricted stock units and warrants to employees of Genmab.
The report is also incorporated by reference into several existing Genmab Form S-8 registration statements, making the announcement part of those employee equity compensation registrations.
Genmab A/S filed a Form 6-K as a foreign private issuer to furnish a company announcement related to insider dealing disclosures. The filing incorporates this update by reference into several existing Form S-8 registration statements for the company’s equity compensation plans, meaning the information becomes part of those registration documents. The attached exhibit covers transactions with shares and linked securities in Genmab A/S made by managerial employees and their closely associated persons.
Genmab A/S, a Denmark-based biotechnology company, submitted a Form 6-K as a foreign private issuer to the U.S. Securities and Exchange Commission for November 2025. The filing primarily makes Genmab’s updated Articles of Association available to U.S. investors as an exhibit.
The report states that this Form 6-K is incorporated by reference into several existing Genmab registration statements on Form S-8, meaning the updated governance document becomes part of those employee share incentive-related registrations. The filing is signed on behalf of the company by Executive Vice President & Chief Financial Officer Anthony Pagano.
Genmab A/S filed a Form 6-K as a foreign private issuer for November 2025. The filing attaches a company announcement dated November 18, 2025 describing a capital increase in Genmab resulting from the exercise of employee warrants.
The Form 6-K is expressly incorporated by reference into Genmab’s existing Form S-8 registration statements, making this capital increase disclosure part of those employee equity compensation-related registrations.
Genmab A/S submitted a Form 6-K as a foreign private issuer for October 2025. The filing makes a company announcement, dated October 14, 2025, available as an exhibit, which covers net sales of DARZALEX (daratumumab) for the third quarter of 2025.
The Form 6-K is also deemed incorporated by reference into several existing Genmab registration statements on Form S-8, meaning the information in this report becomes part of those employee equity compensation-related disclosures.